Stocks in Focus: Sun Pharma, Tata Motors, Voltas, and More

Indian markets ended their five-session winning streak on Friday as a broad-based sell-off, particularly in the IT sector, dragged indices lower. While the Nifty faced resistance near the 24,150 zone, several individual stocks emerged in focus due to strategic acquisitions, capacity expansions, and significant sales milestones.

Sun Pharma and Alembic Pharma Lead Pharma Momentum

India's largest drugmaker, Sun Pharmaceutical Industries Ltd, is set to bolster its product portfolio through a strategic acquisition. The company has agreed to acquire Mumbai-based Innovcare Lifesciences Private Ltd in an all-cash deal valued at approximately $28.7 million (around ₹271.2 crore).

In a similar positive development for the sector, Alembic Pharmaceuticals Ltd announced it has received tentative approval from US health regulators for its generic version of the cancer treatment drug, Binimetinib tablets. These moves signal a period of aggressive portfolio strengthening within the Indian pharmaceutical landscape.

Tata Motors and Voltas Hit Key Growth Milestones

The automotive and consumer durable sectors saw significant news. Tata Motors has demonstrated strong traction in the green mobility space, securing over 3,400 orders for electric commercial vehicles (eCVs). These orders span across the freight, logistics, and passenger mobility segments, highlighting a decisive shift toward electric adoption by Indian commercial fleet operators.

Similarly, Voltas, a Tata Group company and leader in the room air conditioner (RAC) market, reported a massive sales milestone. The company crossed the one-million-unit mark within just the first three months of the 2026-27 financial year, achieving this feat in record time and cementing its market leadership.

Strategic Shifts at ONGC, Tech Mahindra, and Jyothy Labs

Major corporate pivots were also evident in today's market developments. State-run ONGC is undergoing a strategic repositioning; Chairman and CEO Arun Kumar Singh indicated that the company aims to be viewed as a "gas and oil" firm rather than an "oil and gas" company, signaling a heavier focus on gas-led energy production.

In the IT infrastructure space, Tech Mahindra made one of Hyderabad’s largest office leasing moves this year by securing nearly 4 lakh sq. ft. of premium workspace on a long-term lease. Meanwhile, FMCG player Jyothy Labs is expanding its 'Exo' brand into a broader dishwash franchise following the exit of German major Henkel AG & Co. KGaA from its licensing arrangements for Pril and Fa brands in India.

Expansion Plans in Cement and Infrastructure

Dalmia Bharat revealed ambitious growth targets, planning to raise up to ₹4,000 crore through various financial instruments. This capital is earmarked to expand its manufacturing capacity to a massive 110–130 million tonnes per annum by FY31, utilizing a combination of greenfield projects, brownfield expansions, and strategic acquisitions.

Key Takeaways

  • Pharma Expansion: Sun Pharma is investing ₹271.2 crore to acquire Innovcare Lifesciences, while Alembic Pharma gains US regulatory traction for its cancer drug.
  • EV & Consumer Demand: Tata Motors sees high demand for eCVs with 3,400+ orders, and Voltas hits a record 1 million AC sales in just three months.
  • Energy & Infrastructure Shifts: ONGC is pivoting toward a gas-focused energy model, while Dalmia Bharat seeks ₹4,000 crore to scale capacity by FY31.